Agenus (NASDAQ: AGEN) reported Q3 EPS of ($0.33), $0.05 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $19.94 million versus the consensus estimate of $15.6 million.

"We have made solid progress this year," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We expect clinical readouts from six separate antibody programs in 2020 as our robust pace continues. We expect to commence combo trials of our NexGen CTLA-4 with our own PD-1 this month. 2020 is expected to be an important year of data generation, substantial milestone payments and prudent collaborations for Agenus. We look forward to discussing these developments in more detail during our call and at our R&D day on November 15th."

For earnings history and earnings-related data on Agenus (AGEN) click here.